Aryeh Fischer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8150492/publications.pdf

Version: 2024-02-01

84	8,479	87888 38	74163 75
papers	citations	h-index	g-index

88	88	88	4944
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 380, 2518-2528.	27.0	1,025
2	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	6.7	803
3	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine,the, 2016, 4, 708-719.	10.7	754
4	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 147-157.	10.7	410
5	Rheumatoid Arthritisâ€“Interstitial Lung Diseaseâ€“associated Mortality. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 372-378.	5.6	389
6	Interstitial lung disease in connective tissue disorders. Lancet, The, 2012, 380, 689-698.	13.7	338
7	Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease. Journal of Rheumatology, 2013, 40, 640-646.	2.0	316
8	Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal, 2016, 47, 588-596.	6.7	277
9	Connective Tissue Disease-Associated Interstitial Lung Disease. Chest, 2010, 138, 251-256.	0.8	275
10	Scleroderma lung disease. European Respiratory Review, 2013, 22, 6-19.	7.1	230
11	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. Journal of Rheumatology, 2016, 43, 1672-1679.	2.0	222
12	Mycophenolate Mofetil Is Safe, Well Tolerated, and Preserves Lung Function in Patients With Connective Tissue Disease-Related Interstitial Lung Disease. Chest, 2006, 130, 30-36.	0.8	221
13	Characterisation of patients with interstitial pneumonia with autoimmune features. European Respiratory Journal, 2016, 47, 1767-1775.	6.7	219
14	Fibrosing interstitial lung diseases: knowns and unknowns. European Respiratory Review, 2019, 28, 180100.	7.1	191
15	Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respiratory Medicine, 2012, 106, 1040-1047.	2.9	175
16	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Current Medical Research and Opinion, 2019, 35, 2015-2024.	1.9	148
17	Update in the Diagnosis and Management of Pulmonary Vasculitis. Chest, 2006, 129, 452-465.	0.8	138
18	Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respiratory Medicine, 2009, 103, 1719-1724.	2.9	138

#	Article	IF	Citations
19	Clinically Significant Interstitial Lung Disease in Limited Scleroderma. Chest, 2008, 134, 601-605.	0.8	136
20	Rheumatoid Arthritisâ€“Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. Journal of Rheumatology, 2019, 46, 360-369.	2.0	130
21	Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respiratory Medicine, 2013, 107, 1247-1252.	2.9	115
22	Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respiratory Medicine, 2016, 119, 150-154.	2.9	111
23	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 2014, 69, 436-444.	5.6	100
24	Unique Characteristics of Systemic Sclerosis Sine Scleroderma-Associated Interstitial Lung Disease. Chest, 2006, 130, 976-981.	0.8	90
25	Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2009, 136, 841-848.	0.8	90
26	Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. Mayo Clinic Proceedings, 2019, 94, 309-325.	3.0	78
27	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars in Arthritis and Rheumatism, 2014, 44, 55-62.	3.4	69
28	A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest, 2014, 145, 454-463.	0.8	67
29	Interstitial Pneumonia with Autoimmune Features. Annals of the American Thoracic Society, 2019, 16, 525-533.	3.2	62
30	Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respiratory Medicine, 2010, 104, 1350-1355.	2.9	60
31	Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. Journal of Rheumatology, 2006, 33, 1600-5.	2.0	58
32	Connective Tissue Disease-Associated Interstitial Lung Disease. Journal of Intensive Care Medicine, 2015, 30, 392-400.	2.8	49
33	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respiratory Research, 2018, 5, e000289.	3.0	48
34	Minor Salivary Gland Biopsy To Detect Primary SjÃ¶gren Syndrome in Patients With Interstitial Lung Disease. Chest, 2009, 136, 1072-1078.	0.8	47
35	State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. European Respiratory Review, 2018, 27, 170139.	7.1	47
36	Pericardial Abnormalities Predict the Presence of Echocardiographically Defined Pulmonary Arterial Hypertension in Systemic Sclerosis-Related Interstitial Lung Disease. Chest, 2007, 131, 988-992.	0.8	45

#	Article	IF	Citations
37	Connective Tissue Diseaseâ€“Associated Lung Disease. Immunology and Allergy Clinics of North America, 2012, 32, 513-536.	1.9	40
38	Humanistic and cost burden of systemic sclerosis: A review of the literature. Autoimmunity Reviews, 2017, 16, 1147-1154.	5.8	39
39	Update on morbidity and mortality in systemic sclerosisâ€“related interstitial lung disease. Journal of Scleroderma and Related Disorders, 2021, 6, 11-20.	1.7	39
40	Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease. Respiration, 2015, 90, 177-184.	2.6	38
41	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clinical Rheumatology, 2019, 38, 2673-2681.	2.2	38
42	Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. Respiratory Medicine, 2017, 127, 1-6.	2.9	37
43	The lung may play a role in the pathogenesis of rheumatoid arthritis. International Journal of Clinical Rheumatology, 2014, 9, 295-309.	0.3	36
44	A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia. Journal of Rheumatology, 2016, 43, 887-892.	2.0	30
45	Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD). Current Respiratory Medicine Reviews, 2015, 11, 175-183.	0.2	30
46	All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. Journal of Rheumatology, 2018, 45, 235-241.	2.0	29
47	Cross-Disciplinary Collaboration in Connective Tissue Disease-Related Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 159-165.	2.1	28
48	Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) â€“ A subgroup analysis of the ARIES-E clinical trial. Respiratory Medicine, 2016, 117, 254-263.	2.9	26
49	Current approach to connective tissue disease-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2014, 20, 449-456.	2.6	24
50	Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis. Advances in Therapy, 2019, 36, 1100-1113.	2.9	23
51	Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention . Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 283-307.	1.6	23
52	Recent advances in connective tissue disease related interstitial lung disease. Expert Review of Respiratory Medicine, 2017, 11, 591-603.	2.5	21
53	Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients. Journal of Clinical Rheumatology, 2021, 27, e482-e490.	0.9	21
54	Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA₁) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respiratory Research, 2021, 8, e001026.	3.0	20

#	Article	IF	Citations
55	Assessment and management of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32, 2-21.	0.2	19
56	Recentâ€onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care and Research, 2013, 65, 314-323.	3.4	18
57	Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Lung, 2019, 197, 709-713.	3.3	18
58	Primary care assessment of capillaroscopy abnormalities in patients with Raynaudâ€™s phenomenon. Clinical Rheumatology, 2015, 34, 2135-2140.	2.2	16
59	Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Review of Clinical Immunology, 2016, 12, 509-520.	3.0	16
60	Radiologic vignette: Hughes-Stovin syndrome. Arthritis and Rheumatism, 2005, 53, 114-116.	6.7	15
61	Management of Connective Tissue Diseaseâ€“associated Interstitial Lung Disease. Rheumatic Disease Clinics of North America, 2015, 41, 279-294.	1.9	14
62	Interstitial Lung Disease. Journal of Clinical Rheumatology, 2009, 15, 95-99.	0.9	12
63	Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States. Journal of Rheumatology, 2019, 46, 920-927.	2.0	12
64	Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease. Clinical Pulmonary Medicine, 2009, 16, 74-80.	0.3	10
65	Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened. European Respiratory Journal, 2016, 47, 1295-1296.	6.7	10
66	Longitudinal assessment of interstitial pneumonia with autoimmune features is encouraged. Respiratory Medicine, 2017, 132, 267.	2.9	9
67	Connective Tissue Diseaseâ€“related Thoracic Disease. Clinics in Chest Medicine, 2015, 36, 283-297.	2.1	8
68	Interstitial Lung Abnormalities in Rheumatoid Arthritis Are Common and Important. Chest, 2014, 146, 8-10.	0.8	7
69	Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 106-113.	0.8	7
70	Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 475-476.	0.5	5
71	Interstitial Pneumonia with Autoimmune Features. Clinics in Chest Medicine, 2019, 40, 609-616.	2.1	5
72	POINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? Yes. Chest, 2019, 155, 258-260.	0.8	5

#	Article	IF	Citations
73	Development of Autoimmune Interstitial Lung Disease in a Patient with Inclusion Body Myositis. American Journal of Medicine, 2019, 132, e854-e855.	1.5	1
74	Interstitial Pneumonia With Autoimmune Features. , 2022, , 298-306.		1
75	Response. Chest, 2007, 131, 940-941.	0.8	0
76	Reply to Wallis from Iseman and Fischer. Clinical Infectious Diseases, 2008, 47, 1605-1605.	5.8	0
77	Demystifying Lung Disease in the Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2015, 41, xiii-xiv.	1.9	0
78	P100 <break /> Understanding the Determinants of Health-Related Quality of Life in Rheumatoid Arthritis-Associated Interstitial Lung Disease. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	0
79	Rebuttal From Drs Lee and Fischer. Chest, 2019, 155, 263-264.	0.8	0
80	OP0242â€…SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS. , 2019, , .		0
81	OP0017â€…NINTEDANIB REDUCED DECLINE IN FORCED VITAL CAPACITY ACROSS SUBGROUPS OF PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: DATA FROM THE SENSCIS TRIAL. , 2019, , .		0
82	FRI0301â€…GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH NINTEDANIB: DATA FROM THE SENSCIS TRIAL. , 2019, , .		0
83	It takes a village to care for the patient with idiopathic pulmonary fibrosis. Cleveland Clinic Journal of Medicine, 2018, 85, 387-389.	1.3	0
84	Interstitial pneumonia with autoimmune features. , 2019, , 140-152.		0